PriceTargets.com logo

Tandem Diabetes Care - TNDM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $21.63
  • Forecasted Upside: 4.42%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 12 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.71 As of 12/4/2025 05:00 PM ET
▲ +0.78 (3.91%)

This chart shows the closing price for TNDM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

Analyst Price Target is $21.63
▲ +4.42% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $21.63, with a high forecast of $55.00 and a low forecast of $12.00. The average price target represents a 4.42% upside from the last price of $20.71.

This chart shows the closing price for TNDM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 17 contributing investment analysts is to hold stock in Tandem Diabetes Care. This rating has held steady since May 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 12 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Morgan StanleySet TargetEqual Weight ➝ Equal Weight$17.00 ➝ $23.00
11/10/2025BarclaysBoost TargetOverweight ➝ Overweight$51.00 ➝ $55.00
11/10/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$13.00 ➝ $17.00
11/10/2025Truist FinancialReiterated RatingHold ➝ Hold$16.00 ➝ $17.00
11/7/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$13.00 ➝ $14.00
10/21/2025Stifel NicolausInitiated CoverageHold$15.00
10/15/2025Truist FinancialSet TargetHold ➝ Hold$14.00 ➝ $16.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/7/2025CitigroupReiterated RatingNeutral ➝ Neutral$11.00 ➝ $15.00
9/29/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$24.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/8/2025OppenheimerInitiated CoverageOutperform ➝ Outperform$44.00 ➝ $22.00
8/21/2025CitigroupBoost TargetNeutral ➝ Neutral$10.35 ➝ $11.00
8/11/2025Lake Street CapitalDowngradeBuy ➝ Hold$75.00 ➝ $12.00
8/8/2025BarclaysLower TargetOverweight ➝ Overweight$53.00 ➝ $51.00
8/7/2025Canaccord Genuity GroupSet TargetBuy ➝ Buy$59.00 ➝ $24.00
8/7/2025Piper SandlerDowngradeOverweight ➝ Neutral$30.00 ➝ $14.00
8/7/2025UBS GroupLower TargetNeutral ➝ Neutral$20.00 ➝ $17.00
8/7/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.00
8/7/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$45.00 ➝ $25.00
7/9/2025CitigroupReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.00
6/16/2025Truist FinancialInitiated CoverageHold$24.00
5/22/2025CitigroupBoost TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/1/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$58.00 ➝ $59.00
5/1/2025Stifel NicolausLower TargetBuy ➝ Buy$60.00 ➝ $31.00
5/1/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.00
5/1/2025Piper SandlerLower TargetOverweight ➝ Overweight$36.00 ➝ $30.00
5/1/2025Robert W. BairdLower TargetNeutral ➝ Neutral$33.00 ➝ $24.00
4/10/2025MizuhoInitiated CoverageNeutral$20.00
4/9/2025MizuhoUpgradeHold
3/5/2025Morgan StanleyDowngradeOverweight ➝ Equal Weight$45.00 ➝ $22.00
3/4/2025CitigroupDowngradeBuy ➝ Neutral$35.00 ➝ $24.00
3/3/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$42.00 ➝ $24.00
3/3/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $22.00
2/28/2025BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $53.00
2/28/2025Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$35.00 ➝ $25.00
2/27/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$65.00 ➝ $55.00
2/27/2025Robert W. BairdLower TargetNeutral ➝ Neutral$37.00 ➝ $33.00
2/26/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
12/11/2024CitigroupLower TargetBuy ➝ Buy$57.00 ➝ $50.00
12/2/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$45.00 ➝ $45.00
11/8/2024BarclaysBoost TargetOverweight ➝ Overweight$58.00 ➝ $60.00
11/7/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$57.00 ➝ $56.00
11/7/2024Robert W. BairdLower TargetNeutral ➝ Neutral$39.00 ➝ $37.00
11/6/2024Sanford C. BernsteinInitiated CoverageOutperform$42.00
10/4/2024The Goldman Sachs GroupInitiated CoverageNeutral$46.00
10/2/2024Royal Bank Of CanadaInitiated CoverageOutperform$65.00
9/23/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$45.00 ➝ $45.00
8/22/2024Morgan StanleyInitiated CoverageEqual Weight$45.00
8/8/2024Canaccord Genuity GroupInitiated CoverageBuy$57.00
8/8/2024Canaccord Genuity GroupInitiated CoverageBuy$57.00
8/5/2024BarclaysBoost TargetOverweight ➝ Overweight$55.00 ➝ $58.00
8/2/2024UBS GroupUpgradeHold
8/2/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$50.00 ➝ $55.00
8/2/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$36.00 ➝ $39.00
8/2/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$50.00 ➝ $55.00
6/10/2024OppenheimerBoost TargetOutperform ➝ Outperform$47.00 ➝ $58.00
5/30/2024Redburn AtlanticInitiated CoverageBuy$60.00
5/22/2024Lake Street CapitalBoost TargetBuy ➝ Buy$60.00 ➝ $75.00
5/22/2024Stifel NicolausBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
5/22/2024CitigroupUpgradeNeutral ➝ Buy$40.00 ➝ $57.00
5/6/2024BarclaysBoost TargetOverweight ➝ Overweight$39.00 ➝ $55.00
5/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$35.00 ➝ $50.00
5/3/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$28.00 ➝ $36.00
4/29/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$21.00 ➝ $45.00
4/25/2024Leerink PartnrsUpgradeMarket Perform ➝ Outperform
4/25/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$34.00 ➝ $45.00
4/23/2024Stifel NicolausBoost TargetBuy ➝ Buy$37.00 ➝ $40.00
4/3/2024CitigroupBoost TargetNeutral ➝ Neutral$31.00 ➝ $38.00
3/26/2024Stifel NicolausUpgradeHold ➝ Buy$24.00 ➝ $37.00
3/15/2024CitigroupBoost TargetNeutral ➝ Neutral$25.00 ➝ $31.00
2/5/2024Stifel NicolausBoost TargetHold ➝ Hold$17.00 ➝ $24.00
11/2/2023Piper SandlerLower TargetOverweight ➝ Overweight$40.00 ➝ $25.00
10/16/2023Leerink PartnrsReiterated RatingMarket Perform
10/16/2023Leerink PartnersInitiated CoverageMarket Perform$21.00
10/2/2023CitigroupLower TargetNeutral ➝ Neutral$31.00 ➝ $23.00
10/2/2023Jefferies Financial GroupLower TargetBuy ➝ Buy$47.00 ➝ $45.00
8/21/2023CitigroupLower TargetNeutral ➝ Neutral$33.00 ➝ $31.00
8/21/2023Robert W. BairdLower TargetNeutral ➝ Neutral$33.00 ➝ $32.00
8/4/2023BarclaysLower TargetOverweight ➝ Overweight$71.00 ➝ $62.00
8/4/2023TD CowenLower TargetOutperform ➝ Outperform$52.00 ➝ $34.00
8/4/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $30.00
8/4/2023Robert W. BairdLower TargetNeutral ➝ Neutral$38.00 ➝ $33.00
8/4/2023CitigroupDowngradeBuy ➝ Neutral$45.00 ➝ $33.00
6/13/2023Craig HallumLower Target$74.00 ➝ $50.00
6/5/2023CitigroupLower Target$55.00 ➝ $45.00
5/5/2023Bank of AmericaDowngradeNeutral ➝ Underperform$45.00 ➝ $33.00
5/4/2023Stifel NicolausLower Target$45.00 ➝ $40.00
5/4/2023Robert W. BairdLower Target$40.00 ➝ $38.00
4/24/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform
3/28/2023UBS GroupInitiated CoverageNeutral$45.00
2/24/2023Raymond James FinancialLower TargetOutperform$52.00 ➝ $47.00
2/23/2023Craig HallumLower Target$80.00 ➝ $74.00
2/23/2023Piper SandlerLower TargetOverweight$70.00 ➝ $50.00
2/23/2023CowenLower TargetOutperform$61.00 ➝ $52.00
2/23/2023Robert W. BairdLower TargetNeutral$45.00 ➝ $40.00
2/23/2023BarclaysLower Target$76.00 ➝ $71.00
1/26/2023Wolfe ResearchInitiated CoveragePeer Perform
12/12/2022CitigroupBoost Target$50.00 ➝ $55.00
11/15/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$43.00
11/4/2022Raymond James FinancialLower TargetOutperform$92.00 ➝ $52.00
11/3/2022CowenLower Target$107.00 ➝ $61.00
11/3/2022Lake Street CapitalLower Target$150.00 ➝ $60.00
11/3/2022Craig HallumLower Target$105.00 ➝ $80.00
11/3/2022CowenLower Target$107.00 ➝ $61.00
11/3/2022Robert W. BairdLower Target$76.00 ➝ $45.00
11/3/2022Piper SandlerLower TargetOverweight$80.00 ➝ $70.00
10/17/2022BarclaysInitiated CoverageOverweight$75.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$75.00
10/5/2022CitigroupLower Target$98.00 ➝ $75.00
8/9/2022Robert W. BairdLower Target$76.00
8/9/2022Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$82.00 ➝ $49.00
8/4/2022Lake Street CapitalLower Target$200.00 ➝ $150.00
8/4/2022CowenLower Target$141.00 ➝ $107.00
8/4/2022Piper SandlerLower TargetOverweight$120.00 ➝ $80.00
8/4/2022Wells Fargo & CompanyLower TargetOverweight$166.00 ➝ $82.00
8/4/2022Raymond James FinancialLower TargetOutperform$125.00 ➝ $90.00
8/4/2022CowenLower Target$141.00 ➝ $107.00
8/4/2022CitigroupLower Target$107.00 ➝ $98.00
5/17/2022CitigroupLower Target$155.00 ➝ $130.00
5/5/2022OppenheimerLower Target$142.00 ➝ $130.00
5/5/2022Piper SandlerLower Target$170.00 ➝ $120.00
4/18/2022Leerink PartnersReiterated RatingMarket Perform
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral$130.00
2/23/2022Wells Fargo & CompanyBoost TargetOverweight$160.00 ➝ $166.00
2/23/2022CitigroupLower TargetBuy$163.00 ➝ $155.00
2/23/2022Leerink PartnersLower TargetMarket Perform$140.00 ➝ $120.00
1/19/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$137.00 ➝ $160.00
12/7/2021Lake Street CapitalBoost TargetBuy$165.00 ➝ $200.00
12/6/2021Piper SandlerBoost TargetOverweight$140.00 ➝ $150.00
11/4/2021Wells Fargo & CompanyBoost TargetEqual Weight$121.00 ➝ $137.00
11/4/2021Leerink PartnersBoost TargetMarket Perform$135.00 ➝ $140.00
11/4/2021Raymond James FinancialBoost TargetOutperform$120.00 ➝ $138.00
11/4/2021Piper SandlerBoost TargetOverweight$132.00 ➝ $140.00
9/24/2021Leerink PartnersBoost TargetMarket Perform$123.00 ➝ $135.00
8/5/2021Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$102.00 ➝ $123.00
8/5/2021OppenheimerBoost TargetOutperform$135.00 ➝ $140.00
8/5/2021Craig HallumBoost TargetBuy$140.00 ➝ $153.00
8/5/2021Wells Fargo & CompanyBoost TargetEqual Weight$112.00 ➝ $121.00
8/5/2021Raymond James FinancialBoost TargetOutperform$115.00 ➝ $120.00
5/24/2021BarclaysInitiated CoverageUnderweight$90.00
5/6/2021OppenheimerBoost Target$130.00 ➝ $135.00
5/6/2021Leerink PartnersBoost TargetMarket Perform$95.00 ➝ $102.00
4/1/2021Leerink PartnersLower TargetMarket Perform$115.00 ➝ $95.00
3/31/2021OppenheimerReiterated RatingBuy
2/25/2021Lake Street CapitalBoost TargetBuy$137.00 ➝ $150.00
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$105.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 49 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 33 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 13 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 18 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 39 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 20 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 20 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 31 very positive mentions
  • 31 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 31 very positive mentions
  • 31 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tandem Diabetes Care logo
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $20.71
Low: $19.70
High: $20.77

50 Day Range

MA: $16.34
Low: $11.79
High: $21.84

52 Week Range

Now: $20.71
Low: $9.98
High: $38.28

Volume

1,211,304 shs

Average Volume

2,727,369 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Lake Street Capital, Mizuho, Morgan Stanley, Oppenheimer Holdings, Inc., Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

0 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $21.63, suggesting a possible upside of 4.4%. Barclays PLC has the highest price target set, predicting TNDM will reach $55.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $12.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 1 sell rating, 12 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TNDM, but not buy more shares or sell existing shares.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

Other companies that are similar to Tandem Diabetes Care include TransMedics Group, Inspire Medical Systems, LivaNova, Envista and Liquidia. Learn More about companies similar to Tandem Diabetes Care.

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected]. The official website for Tandem Diabetes Care is www.tandemdiabetes.com. Learn More about contacing Tandem Diabetes Care investor relations.